707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Canada
https://hemostemix.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, CEO & Director | 308k | N/A | 1962 |
Ms. Christina Wu CPA | Interim Chief Financial Officer | 65.38k | N/A | N/A |
Mr. Peter Pavlin | Vice President of Operations | N/A | N/A | N/A |
Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer | N/A | N/A | N/A |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.